In October 2024, Omron Healthcare received de novo authorisation from the US Food and Drugs Administration (FDA) to market ...

The fund posted returns of 0.00% (Institutional shares) and 0.00% (Investor A shares, without sales charge) for the third ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Quanta Dialysis Technologies has raised $60 million to expand its U.S. commercial presence for its Quanta dialysis system.

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

Stocks rebounded in a volatile session marked by a flurry of geopolitical headlines, with Nvidia Corp. climbing in the run-up to its results.

“Rising geopolitical tensions have been and continue to be a risk for markets,” said Gaurav Mallik at Pallas Capital Advisors. The uncertainty “is a recipe” for volatility, he added. The S&P 500 fell ...